Univ. Prof. Dr. Bernd Jilma
Medical University of Vienna, Department of Clinical Pharmacology, Währinger Gürtel 18-20, 1090 Vienna
know-how and research interests:
Our group is interested in platelet function and coagulation in various clinical settings but particularly emergencies, and critically ill patients with disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, resuscitated as well as stroke patients. We are using a human endotoxemia model to characterize the mechanism of action of various investigational anticoagulants and anti-inflammatory drugs in phase I trials, and have recently established a model of endotoxin instillation into the lung. We also focus on high on treatment platelet reactivity in patients taking P2Y12 inhibitors, and have been investigating drug-drug interactions of anti-platelet drugs, and the pharmacodynamic effects of aptamers on coagulation and platelets
Coagulation and platelet function in inflammation and critically ill
techniques and infrastructure of the research group:
Phase I research ward, human endotoxemia model, endotoxin instillation in the lung, various models of extracorporeal circulation, platelet function analysis, analysis of in vivo markers of clotting, flow cytometry, enzyme linked immunoassays, chemoluminescence assays, RT-PCR, high power liquid chromatography, expression and purification of recombinant proteins as well as mass spectrometry in collaboration with BOKU & KIMCL
5 selected publications:
Schwameis M, Roppenser B, Firbas C, Gruener CS, Model N, Stich N, Roetzer A, Buchtele N, Jilma B, Eibl MM: Safety, tolerability, and immunogenicity of a recombinant toxic shock syndrome toxin (rTSST)-1 variant vaccine: a randomised, double-blind, adjuvant-controlled, dose escalation first-in-man trial. Lancet Infect Dis. 2016 Jun 10. pii: S1473-3099(16)30115-3
Peyvandi F, Sully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni W, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichs H, Duby C, Tersago D; TITAN Investigators. Caplacizumab for Acquired Thrombotic Thrombozytopenic Purpura. N Engl J Med. 2016 Feb 11;374(6):511-522.
Ramsauer K, Schwameis M, Firbas C, Müllner M, Putnak RJ, Thomas SJ, Desprès P, Tauber E, Jilma B, Tangy F: Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis. 2015 Feb 27.
Hobl EL, Stimpfl T, Ebner J, Schörgenhofer C, Derhaschnig U, Sunder-Plassmann R, Jilma-Stohlawetz P, Mannharter C, Posch M, Jilma B: Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2014 Feb 25;63(7):630-5
Siller-Matula J, Lang IM, Christ G, Jilma B: Calcium-Channel Blockers Reduce the Antiplatelet Effect of Clopidogrel. J Am Coll Cardiol 2008, 52:1557-63